There are no negatives to OCAT RPE now.
Phase 1 -Success
NSDQ -Success
Clean Balance Sheet
No Debt
No Dilution
It's VERY doubtful they won't find non-dilutive
funding with the above factors.
It might seem risky to test for deletion of
the immunosuppression drug requirement.
But perhaps these drugs have unpleasant
side effects, and the time spent will be
worth the risk for the comfort of not using them.
And the time spent will be recovered when phase 2
begins.
In any case, you can always go back to using them
if any problems arise.
So, there are no negatives to OCAT RPE.
People said OCAT RPE would never up list -Wrong
People said OCAT RPE would plunge from dilution -Wrong
The naysayers are continually moving their goal posts.
And are forced into simple minded criticisms from
the time before phase 1 completion.
The share price is holding steady near the $6 level,
and it looks very much like some sort of accumulation
algorithm is running. It's only a matter of time now,
not if !
